American Airline jet flying with NYC skyline in background
April 25, 2024

U.S. Yields Surge to 2024 Highs Amid Economic Concerns: Markets Wrap

Economic Slowdown and Inflation Spike Challenge Fed’s Soft-Landing Strategy Wall Street faced a tough trading session as new economic data showed a significant slowdown in the U.S. economy alongside persistent inflation, complicating the Federal Reserve’s policy path. The disappointing figures have triggered fears of stagflation, causing a sell-off in Treasuries and pushing yields to their… [Read More]
April 25, 2024

BioStem Technologies Prepares to Uplist to Senior Exchange

BioStem Technologies (OTC: BSEM) has completed a two year audit as part of its preparations for uplisting to a senior stock exchange. The company announced today that it anticipates its uplisting will help to further validate BioStem’s market position, attract a broader investor base, and enhance shareholder value.   “Completing this rigorous two-year audit underscores… [Read More]
April 25, 2024

SKYX Enters Strategic Partnership with World-Leading Lighting Supplier Opening Access to US, Chinese, and European Markets

Disruptive smart platform technology company, SKYX (Nasdaq: SKYX) has increased its access to professional and retail customers in US, Chinese and European markets after entering an important new partnership with the world-leading Chinese lighting supplier and manufacturer, Ruee Appliances. The agreement introduces operational and logistical efficiencies and is expected to substantially enhance gross margins on… [Read More]
April 24, 2024

Hope for Allergy Sufferers as Altamira Publishes Positive Results from Rhinitis Study

Results from Altamira Therapeutics’ (Nasdaq:CYTO) NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) has been accepted for publication in Allergy, one of the highest-ranking journals in the field of allergology. Bentrio is an OTC nasal spray for allergic rhinitis and a commercial-stage legacy asset for Altamira. Bentrio (AM-301) is a drug-free… [Read More]
April 24, 2024

BranchOut Food Soars on Latest Deal with Nation’s Largest Retailer

Shares in disruptive food technology company, BranchOut Food (Nasdaq: BOF) soared more than 80% in morning trading on Wednesday after the company announced it had inked a third deal with one of the nation’s largest retailers. BranchOut Food stated that the new commitment from the retailer, valued at $300,000 brings the total annualized value of… [Read More]
Double exposure of business handshake and oil refinery plant. Business people shaking hands in the office. Finishing successful meeting
April 24, 2024

Update On Pending Merger Between Verde Bio and SensaSure Technologies

Oil and gas company Verde Bio (VBHI) issued an update regarding its pending merger with SensaSure Technologies (SSTC). In the update the company announced that the registration statement on Form S-4 has been declared effective by the Securities and Exchange Commission. A special meeting will be held for each company’s shareholders on May 9th 2024…. [Read More]
April 24, 2024

Positive Results for Alto Neuroscience in Phase 1 Schizophrenia Study

Alto Neuroscience, Inc. (NYSE: ANRO) has announced positive results from its Phase 1 study of ALTO-101 for cognitive impairment associated with schizophrenia (CIAS). The study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administration. Alto ended the day up 1.76% and rose a further… [Read More]
April 24, 2024

Silo Pharma Reports Positive Results from PTSD Study

Silo Pharma, Inc. (Nasdaq: SILO) has announced positive data from its recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University under a sponsored research agreement and option. Commenting on the positive results, Silo CEO… [Read More]
April 24, 2024

Reviva Pharmaceuticals’ Phase 3 Schizophrenia Program Receives FDA Acceptance

Reviva Pharmaceuticals (Nasdaq: RVPH) has received acceptance from the FDA for its 4-week registrational Phase 3 program for brilaroxazine in schizophrenia. Reviva’s RECOVER-2 study is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter, 4-week trial designed to assess the safety and efficacy of brilaroxazine in approximately 450 patients with acute schizophrenia compared to placebo. The… [Read More]
3D image of stomach and instetines
April 23, 2024

Palisade Bio Collaboration to Advance Precision Medicine for Ulcerative Colitis

Biopharmaceutical company, Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, to advance precision medicine for ulcerative colitis (UC) therapy. The company’s share price rose nearly 30% in intraday trading following the news. The collaboration will provide Palisade Bio with access to advanced bioinformatics tools… [Read More]